

Initial Date: 07/19/2023

Revised Date: Section: 9-15R

### **Atropine**

Pharmacological Category: Anticholinergic Agent; Antidote; Antispasmodic Agent, Gastrointestinal

Routes: IV/IO

#### Indications:

1. Severe symptomatic bradycardia

2. Exposure to organophosphates or other nerve agents when Nerve Agent (NA) Antidote Kit is not available.

#### **Expected effects:**

- 1. Increased heart rate
- 2. Dilated pupils

**Note:** For Nerve Agent/Organophosphate Pesticide Exposure, when NA Antidote kit is not available, pralidoxime should also be administered in conjunction with atropine when available.

#### Dosing: CRASHING ADULT/IMPENDING ARREST

Indication: Bradycardia

Adults administer:

1. Atropine 1 mg IV/IO

#### Dosing: ADULT BRADYCARDIA

Indication: Bradycardia Adults administer:

1. Atropine 1 mg IV/IO rapid push repeating every 3-5 minutes to a total dose of 3 mg

#### **Dosing: PEDIATRIC BRADYCARDIA**

Indication: Bradycardia Pediatrics administer:

- 1. According to MI MEDIC Cards
- 2. If MI MEDIC Cards are not available administer:
  - a. Atropine 0.02 mg/kg IV/IO (minimum dose 0.1 mg, maximum single dose 0.5 mg). May repeat once in 5 minutes, if effective.

#### Dosing: NERVE AGENT/ORGANOPHOSPHATE PESTICIDE EXPOSURE

Indication: Nerve Agent/Organophosphate Pesticide Exposure when NA Antidote Kit is not available. See chart below for number of NA kits required based on age and symptoms.

#### Adults administer:

1. Atropine 2 mg IM/IV for every 1 NA kit that is required.

Pediatrics administer:



Initial Date: 07/19/2023
Revised Date: Section: 9-15R

- 1. According to MI MEDIC cards
- 2. If MI MEDIC cards are not available refer to CHART A below for atropine dosage.
- 3. Refer to CHART B below and administer 2 mg atropine IV/IM for every one NA Antidote kit required.

#### **CHART A**

### Nerve Agent/Organophosphate Antidotes/Countermeasures

Weight	Age	Duodote <sup>1</sup> Mod-Severe Sxs	Atropen <sup>2</sup> (1 mg) Mod- Severe Sxs	Atropine Dose (0.1 mg/kg) IM/IV/IO	Atropine Vial <sup>2</sup> (1 mg/mL)	Cardiac Atropine <sup>2,3</sup> (1 mg/10 mL)	Midazolam <sup>4</sup> (10 mg/2 mL) IM/IV/IO
3-5 kg (6-11 lbs)	0-2 months	1	1	0.4 mg	0.4 mL	4 mL	0.1 mL
6-7 kg (13-16 lbs)	3-6 months	1	1	0.7 mg	0.7 mL	7 mL	0.2 mL
8-9 kg (17-20 lbs)	7-10 months	1	1	0.9 mg	0.9 mL	9 mL	0.2 mL
10-11 (21-25 lbs)	11-18 months	1	1	1 mg	1 mL	10 mL	0.2 mL
12-14 kg (26-31 lbs)	19-35 months	1	2	1.3 mg	1.3 mL	13 mL	0.25 mL
15-18 kg (32-40 lbs)	3-4 years	1	2	1.6 mg	1.6 mL	16 mL	0.3 mL
19-23 kg (41-51)	5-6 years	1	2	2 mg	2 mL	20 mL	0.4 mL
24-29 kg (52-64)	7-9 years	2	3	2.6 mg	2.6 mL	26 mL	0.5 mL
30-36 kg (65-79 lbs)	10-14 years	2	3	3.3 mg	3.3 mL	33 mL	0.6 mL
Adult	>14 years	2 to 3	4 to 6	4 to 6 mg	4 to 6 mL	40-60 mL	2 mL

<sup>1</sup>Preferred initial autoinjector, <sup>2</sup>May Repeat atropine every 5 minutes until airway secretions decrease (6 mg maximum), <sup>3</sup>Not available in MEDDRUN, <sup>4</sup>Patients with severe symptoms should receive midazolam even if not obviously seizing

CHART B

MCA Name MCA Board Approval MCA Implementation Date MDHHS Approval: 7/19/23



Initial Date: 07/19/2023

Revised Date: Section: 9-15R

	Clinical Findings	Signs/Symptoms	Required Conditions	NA Kits To Be Delivered
SELF-RESCUE	Threshold Symptoms	<ul> <li>Dim vision</li> <li>Increased tearing</li> <li>Runny nose</li> <li>Nausea/vomiting</li> <li>Abdominal cramps</li> <li>Shortness of breath</li> </ul>	Threshold Symptoms -and- Positive evidence of nerve agent or OPP on site  Medical Control Order	1 NA Kit (self-rescue)
ADULT PATIENT > 8 years of age	Mild Symptoms and Signs	<ul> <li>Increased tearing</li> <li>Increased salivation</li> <li>Dim Vision</li> <li>Runny nose</li> <li>Sweating</li> <li>Nausea/vomiting</li> <li>Abdominal cramps</li> <li>Diarrhea</li> </ul>	Medical Control Order	1 NA Kit
TIENT >	Moderate Symptoms and Signs	<ul> <li>Constricted pupils</li> <li>Difficulty         breathing     </li> <li>Severe vomiting</li> </ul>	Constricted Pupils	2 NA Kits
ADULT PA	Severe Signs	<ul> <li>Constricted pupils</li> <li>Unconsciousness</li> <li>Seizures</li> <li>Severe difficulty breathing</li> </ul>	Constricted Pupils	3 NA Kits (If 3 NA Kits are used, administer 1st dose of available benzodiazepine)



Initial Date: 07/19/2023

Revised Date: Section: 9-15R

	Clinical Findings	Signs/Symptoms	Required Conditions	NA Kits To Be Delivered
PEDIATRIC < 8 years of age	Pediatric Patient with Non-Severe Signs/Symptoms	<ul> <li>Mild or moderate symptoms as above</li> </ul>	Threshold Symptoms -and- Positive evidence of nerve agent or OPP on site  Medical Control Order	1 NA Kit
	Pediatric Patient with Severe Signs/Symptoms	<ul><li>Constricted pupils</li><li>Unconsciousness</li><li>Seizures</li><li>Severe difficulty breathing</li></ul>	Severe breathing difficulty Weakness	1 NA Kit

### **Used in the Following Protocols**

Crashing Adult/Impending Arrest (Section 3 Adult Treatment)

Bradycardia (Section 5 Adult Cardiac)

Pediatric Bradycardia (Section 6 Pediatric Cardiac)

Nerve Agent/Organophosphate Pesticide Exposure (Section 10 Special Operations)